Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Pfizer Makes Vaccines Entry With PowderMed Acquisition

This article was originally published in The Pink Sheet Daily

Executive Summary

Acquisition of the U.K. company will give Pfizer a pipeline of DNA-based vaccines that could surpass cell-based technology, firm says.

You may also be interested in...



GSK Spins Out Pain Assets, Raises $35.4m

UK-based Convergence's lead asset starts Phase II in neuropathic pain

GSK Spins Out Pain Assets, Raises $35.4m

UK-based Convergence's lead asset starts Phase II in neuropathic pain

Pfizer Plans Four New Products A Year Starting In 2011

Company highlights strength of pipeline at R&D briefing, but says it will rely on a near-term licensing strategy to address “gaps.”

Related Content

Topics

Latest Headlines
See All
UsernamePublicRestriction

Register

PS063337

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel